Abstract
A Corrigendum onTargeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?
by Chan C, Lustig M, Baumann N, Valerius T, van Tetering G and Leusen JHW (2022) 13:932155. doi: 10.3389/fimmu.2022.932155
by Chan C, Lustig M, Baumann N, Valerius T, van Tetering G and Leusen JHW (2022) 13:932155. doi: 10.3389/fimmu.2022.932155
| Original language | English |
|---|---|
| Article number | 1017924 |
| Pages (from-to) | 1-2 |
| Journal | Frontiers in Immunology |
| Volume | 13 |
| DOIs |
|
| Publication status | Published - 13 Sept 2022 |
Keywords
- antibodies
- cancer immonotherapy
- CD47-SIRPalpha axis
- IgA
- immune checkpoint
- macrophages
- myeloid checkpoints
- neutrophils (PMNs)
Fingerprint
Dive into the research topics of 'Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver